# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Neurofibromatosis type 2

Neurofibromatosis 2 (NF2)Bilateral Acoustic NeurofibromatosisBANF Acoustic Neurinoma
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 55 results.
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Status: Unknown status
Last Changed: Feb 10, 2017
First Received: Oct 14, 2016
Disease(s): Vestibular Schwannoma, Neurofibromatosis Type 2
Intervention(s): Icotinib
Locations: Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Status: Completed
Last Changed: Feb 10, 2017
First Received: Apr 04, 2014
Disease(s): Vestibular Schwannoma, Neurofibromatosis Type 2
Intervention(s): Endostatin
Locations: Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Status: Active, not recruiting
Last Changed: Aug 29, 2019
First Received: May 02, 2014
Disease(s): Neurofibromatosis Type 2, Vestibular Schwannomas
Intervention(s): Axitinib
Locations: NYU Langone Medical Center, New York, New York, United States
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Status: Completed
Last Changed: Jul 18, 2017
First Received: Aug 18, 2011
Disease(s): Neurofibromatosis Type II
Intervention(s): Everolimus (RAD001) , Afinitor®
Locations: New York University Medical Center, New York, New York, United States
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Status: Completed
Last Changed: Aug 27, 2018
First Received: Sep 23, 2010
Disease(s): Vestibular Schwannoma, Neurofibromatosis Type 2
Intervention(s): bevacizumab, laboratory biomarker analysis, quality-of-life assessment
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
National Cancer Institute, Rockville, Maryland, United States
Massachusetts General Hospital, Charlestown, Massachusetts, United States
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Status: Active, not recruiting
Last Changed: Feb 27, 2020
First Received: Apr 29, 2011
Disease(s): Neurofibromatosis Type 2, Neuroma, Acoustic
Intervention(s): RAD001, everolimus
Locations: University of California Los Angeles, Los Angeles, California, United States
PTC299 for Treatment of Neurofibromatosis Type 2
Status: Terminated
Last Changed: Apr 12, 2019
First Received: Jun 01, 2009
Disease(s): Neurofibromatosis 2
Intervention(s): PTC299
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Status: Active, not recruiting
Last Changed: Aug 05, 2020
First Received: Jan 14, 2013
Disease(s): Neurofibromatosis Type 2, Progressive Vestibular Schwannomas
Intervention(s): Bevacizumab
Locations: Children's Hospital Los Angeles, Los Angeles, California, United States
Children's National Medical Center, Washington, District of Columbia, United States
Children's HealthCare of Atlanta, Atlanta, Georgia, United States
University of Chicago, Chicago, Illinois, United States
Indiana Unversity, Indianapolis, Indiana, United States
... and 8 other locations.
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Status: No longer available
Last Changed: Dec 06, 2019
First Received: Oct 28, 2015
Disease(s): Neurofibromatosis Type 2, Severe Profound Sensorineural Hearing Loss
Intervention(s): Nucleus Profile ABI541 Auditory Brainstem Implant
Locations: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Status: Completed
Last Changed: May 23, 2017
First Received: Dec 13, 2011
Disease(s): Neurofibromatosis 2
Intervention(s): RAD001
Locations: Hôpital Beaujon, 100 boulevard du Général Leclerc, Clichy, France